FinDogFinDog
Monday, October 12, 2026Closing data · 4:00 PM ET
English
Log in

Alnylam Pharmaceuticals · Multi-Quarter Financial Trends

16 quarters · As reported by the company · Amounts in USD billions← ALNY
QuarterPeriod EndRevenue ($B)YoYGross MarginOperating Income ($B)Net Income ($B)Net MarginFree Cash Flow ($B)EPSBuybacks ($B)Dividends ($B)
FY2026 Q22026-06-301.29+66.9%76.9%0.230.1612.7%—1.21——
FY2025 Q42025-12-311.10+84.9%75.6%0.130.1514.0%0.141.18——
FY2025 Q32025-09-301.25+149.3%84.2%0.370.2520.1%0.341.84——
FY2025 Q22025-06-300.77+17.3%81.6%-0.02-0.07-9.3%0.11-0.55——
FY2025 Q12025-03-310.59+20.2%88.2%0.02-0.02-3.1%-0.13-0.14——
FY2024 Q42024-12-310.59+34.9%82.7%-0.11-0.08-14.1%-0.10-0.66——
FY2024 Q32024-09-300.50−33.3%83.6%-0.08-0.11-22.3%0.04-0.87——
FY2024 Q22024-06-300.66+107.0%89.8%0.05-0.02-2.6%0.12-0.13——
FY2024 Q12024-03-310.49+54.8%89.0%-0.04-0.07-13.3%-0.09-0.52——
FY2023 Q42023-12-310.44+31.2%83.6%-0.12-0.14-31.4%-0.05-1.06——
FY2023 Q32023-09-300.75+184.0%89.4%0.210.1519.7%0.341.15——
FY2023 Q22023-06-300.32+41.8%76.4%-0.23-0.28-86.6%-0.07-2.21——
FY2023 Q12023-03-310.32—87.0%-0.15-0.17-54.5%-0.18-1.40——
FY2022 Q42022-12-310.34—86.2%-0.19-0.21-61.9%-0.15-1.69——
FY2022 Q32022-09-300.26—86.2%-0.26-0.41-153.6%-0.13-3.32——
FY2022 Q22022-06-300.22—84.9%-0.19-0.28-123.4%-0.14-2.29——

Quarterly figures come from the company's 10-Q and 10-K filings. The fourth quarter is derived as the full year minus the first three quarters; cash flow items are converted from fiscal year-to-date totals into single quarters.